bioAffinity Technologies, Inc. (BIAFW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysts estimate Earnings Per Share (EPS) of $-20.70 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.73 vs est $-20.70 (beat +96.5%). 2025: actual $-8.66 vs est $-14.40 (beat +39.9%). Analyst accuracy: 0%.
EPS Estimates — BIAFW
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.73
vs Est –$20.70
▲ 2,735.6% off
2025
Actual –$8.66
vs Est –$14.40
▲ 66.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BIAFW
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.009B
vs Est $0.010B
▼ 2.2% off
2025
Actual $0.006B
vs Est $0.006B
▲ 1.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
